Market Research Report
Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By End Use, By Product (Column-based, Array-based, Services), By Application (PCR Primer, FISH), And Segment Forecasts, 2018 - 2025
|Published by||Grand View Research, Inc.||Product code||744619|
|Published||Content info||210 Pages
Delivery time: 2-3 business days
|Oligonucleotide Synthesis Market Size, Share & Trends Analysis Report By End Use, By Product (Column-based, Array-based, Services), By Application (PCR Primer, FISH), And Segment Forecasts, 2018 - 2025|
|Published: October 5, 2018||Content info: 210 Pages||
The global oligonucleotide synthesis market size is expected to reach USD 3.9 billion by 2025 at a 12.4% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Continuous rise in usage of oligonucleotide synthesis across various aspects of human health management, from molecular diagnostics to therapeutics, is spurring revenue growth.
The recent success of oligonucleotide-based drugs in medicine due to increase in number of FDA-approved products is anticipated to boost revenue generation in this market. As of September 2017, there are six approved oligonucleotide therapeutic products.
A substantial number of oligos are being investigated for their usage in targeting various infectious diseases. For instance, dsDNA thioaptamers are reported to target the ribonuclease H (RNase H) domain of HIV-RT and are demonstrated to inhibit HIV-RT when used in vitro.
In addition, demand for cancer-related thioapatmers that can detect presence as well as target tumor growth factors, such as TGF-B, is on a continuous rise. This, in turn, has led to increase in investments for exploring the significance of custom oligonucleotide synthesis in cancer research.
Some of the key companies in the market are: BioAutomation; Integrated DNA Technologies, Inc.; LGC Biosearch Technologies; Agilent Technologies; GE Healthcare Dharmacon Inc.; and Gene Scripts.